Wikisage, the free encyclopedia of the second generation, is digital heritage

Belzutifan: Difference between revisions

From Wikisage
Jump to navigation Jump to search
(dutch wikiLink)
No edit summary
Line 16: Line 16:


{{wikidata|Q27456641}}
{{wikidata|Q27456641}}
{{refs}}
[[nl:Belzutifan]]
[[nl:Belzutifan]]

Revision as of 23:39, 13 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

belzutifan

Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

Q27456641 at Wikidata  Interwiki via Wikidata


References

References: